• F Peyron, M Wallon, C Liou, and P Garner.
• Laboratoire de Parasitologie, Mycologie Medicale et Pathologie Exotique, Universite Claude Bernard - Lyon 1, 8 avenue Rockefeller, 69373 Lyon, Cedex 08, France. peyron@cismsun.univ-lyon1.fr
• Cochrane Db Syst Rev. 2000 Jan 1 (2): CD001684.

BackgroundToxoplasmosis is a widespread parasitic disease and usually causes no symptoms. However, infection of pregnant women may cause congenital infection, resulting potentially in mental retardation and blindness in the infant.ObjectivesThe objective of this review was to assess whether or not treating toxoplasmosis in pregnancy reduces the risk of congenital toxoplasma infection and improves infant outcomes.Search StrategyThe Cochrane Pregnancy and Childbirth Group trials register was searched. An electronic search was performed using the key words 'congenital and toxoplasmosis' on the following databases: MEDLINE (1966-07/1997), Embase (1993-07/1997), Pascal (French) (1990-1997), Biological Abstracts (1993-1995) and the Cochrane Controlled Trials Register. There was also contact with experts in the field, including those in the European Research Network on Congenital Toxoplasmosis.Selection CriteriaRandomised controlled trials of antibiotic treatment versus no treatment of pregnant women with proven or likely acute Toxoplasma infection, with outcomes in the children reported. We also inspected relevant reports of less robust experimental studies in which there were (non randomly allocated) control groups, although it was not planned to include such data in the primary analysis.Data Collection And AnalysisReports of possibly eligible studies were scrutinised by two investigators.Main ResultsOut of the 2591 papers identified, none met the inclusion criteria.Reviewer's ConclusionsDespite the large number of studies performed over the last three decades we still do not know whether antenatal treatment in women with presumed toxoplasmosis reduces the congenital transmission of Toxoplasma gondii. Screening is expensive, so we need to evaluate the effects of treatment, and the impact of screening programmes. In countries where screening or treatment is not routine, these technologies should not be introduced outside the context of a carefully controlled trial.

8 keywords...

hide…